Biotech Values

[biocqr]

CRBP > Corbus looks interesting on a number of fronts.. + only $90M mc. I can't find any other programs that target CB2...looks like Resunab could have therapeutic use in a broad range of inflammatory conditions. Not much cash on hand but they have enough to last in 1H 2016... Q burn is only $1.3M.

I was concerned that they skipped the IPO route but this explains it...

http://www.bizjournals.com/boston/blog/bioflash/2015/04/bay-state-s-newest-nasdaq-listed-biotech-corbus.html?ana=twt&page=all

CEO Yuval Cohen of Corbus (Nasdaq: CRBP) says the speed at which the company has gotten up and running has a lot to do with the way it went public, which was not through a traditional initial public offering, nor a reverse merger into another publicly-traded firm.
Rather, the company was formed under its current name last May and completed a $10 million private placement the following month, about 25 percent of which came from institutional investors like Knoll Capital Management and Perceptive Advisors. The rest, Cohen said, came from “retail, individual investors,” which includes Mark Tepper, a former executive at Bristol Myers Squibb and other companies, and Sumner Burstein, professor emeritus at UMass Medical School.
Cohen says he registered those shares of equity with the SEC – rather than selling them and raising new funding, as in an IPO – and became an over-the-counter stock. On Friday, it uplisted to the Nasdaq, and as of the close of markets Tuesday, it had a market capitalization of $72 million, according to Bloomberg.
Cohen said the whole series of events happened faster than the company itself had promised to its investors, and ended up being better for those investors than an IPO.
“We sort of skipped a whole series of dilutive rounds,” he said.